Clinical trials: Anticoagulation in Dialysis Patients
Atrial Fibrillation, End Stage Renal Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
- Trial name
- RENAL-AF (NCT02942407)
- Testing
- apixaban, warfarin
- Where
- 58 sites in United States
- Volunteers
- 154 people
- Sponsor
- Christopher Granger, MD
Thromboembolism, Hemodialysis
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
The purpose of this study is to better understand if either dalteparin or tinzaparin is a better drug to use in dialysis patients on blood thinners who are at high risk of developing blood clots and need surgery.
- Trial name
- NCT00260988
- Testing
- Fragmin (dalteparin), Innohep (tinzaparin)
- Where
- 2 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Ottawa Hospital Research Institute
Acute Kidney Injury, Hemodialysis
Comparison of Slow Efficiency Daily Dialysis (SLEDD) With Unfractionated Heparin Versus Citrasate in Critically Ill Patients.
The purpose of this study is to compare the feasibility, safety and efficacy of hemodialysis with unfractionated heparin compared to hemodialysis with Citrasate in Critically Ill Patients.
- Trial name
- NCT01228292
- Testing
- Unfractionated heparin, Citrasate
- Where
- Belgium
- Volunteers
- 250 people
- Sponsor
- University Hospital, Antwerp
Dialysis
Citrate Anticoagulation vs. Heparin-Coated Dialyzers
Hemodialysis causes contact activation of the coagulation pathway (1). For this reason, unfractionated or low molecular weight heparins are administered in daily practice to prevent thrombosis of the dialyzer and blood circuit…
- Trial name
- NCT00395824
- Testing
- anticoagulation procedure
- Where
- Belgium
- Volunteers
- 33 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Kidney Failure, Critically Ill
Hemodialysis Without Anticoagulation in Intensive Care Unit
The purpose of this study is to determine the safety and operative efficacy of intermittent hemodialysis without anticoagulation with saline flushes or Nephral 400ST in patients at high risk of bleeding
- Conditions
- Kidney Failure, Critically Ill, Hemorrhage
- Trial name
- NCT00242398
- Testing
- AN69 ST
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Départemental
Hemodialysis Complication, Acute Kidney Injury
Evaluation of Regional Anticoagulation With Citrate in Extended Hemodialysis
Data on regional citrate anticoagulation in patients with acute kidney injury (AKI) treated by hybrid or extended dialysis are scarce and heterogeneous.
- Conditions
- Hemodialysis Complication, Acute Kidney Injury, Anticoagulant Toxicity
- Trial name
- NCT04297839
- Testing
- Citrate Anticoagulation Solution, Control Group (heparin or continuous saline)
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- University of Sao Paulo General Hospital
Hemodialysis, Coagulation
Optimisation of Anticoagulation in Patients on Nocturnal Hemodialysis
To avoid clotting during extracorporeal treatment, an anticoagulant is added to the circuit, resulting in an increased risk for bleeding complications.
- Trial name
- NCT05204810
- Testing
- Anticoagulation strategy, Blood sampling, Scanning of hemodialyzer with micro-computed tomography
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Chronic Hemolysis, VKA
Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA
Use HeprAN ™ membrane (coated with heparin) should be allow the success of dialysis sessions, with adequate dialysis parameters, in patients treated by long-term anticoagulation with VKA, without addition of heparin perdialytic.
- Conditions
- Chronic Hemolysis, VKA, Anticoagulants / Administration & Dosage, Coated Materials
- Trial name
- REMARK (NCT04462614)
- Testing
- Decrease per-dialytic heparin therapy
- Where
- France
- Volunteers
- 49 people
- Sponsor
- CHU de Reims
Complication of Dialysis
Observational Study of Citrate Based Dialysis in Pediatric Patients Receiving Hemodialysis
Providing hemodialysis requires the use of an extracorporeal circuit which must be anticoagulated. Inadequate anticoagulation can result in the dialyzer clotting with decreased circuit blood flows, inefficient dialysis and even…
- Trial name
- NCT01590550
- Testing
- Use of citrate based dialysate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Loma Linda University
Chronic Kidney Diseases, Atrial Fibrillation
Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
Objective: To study the efficacy and safety of apixaban as stroke prophylaxis in patients with chronic kidney disease (CKD) stage 5 and atrial fibrillation (AF) with or without dialysis treatment.
- Conditions
- Chronic Kidney Diseases, Atrial Fibrillation, Stroke, Intracerebral Hemorrhage
- Trial name
- SACK (NCT05679024)
- Testing
- Apixaban 2.5 milligram Oral Tablet
- Where
- 34 sites in Finland, Iceland and 2 more
- Volunteers
- 1,400 people
- Sponsor
- Region Stockholm
Atrial Fibrillation, Peritoneal Dialysis Complication
Safety and Efficacy of Apixaban Versus Warfarin in Peritoneal Dialysis Patients With Non Valvular Atrial Fibrillation: a Prospective, Randomised, Open-label, Blinded End-point Trial (APIDP2)
Introduction: Several randomised controlled trials have demonstrated that novel oral anticoagulants (NOACs) are safer compared to vitamin K antagonists for the management of non valvular atrial fibrillation (NVAF) to prevent…
- Trial name
- APIDP2 (NCT06045858)
- Testing
- Anticoagulation Agents
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
Anticoagulation in Dialysis Patients
Comparison of Point of Care to Lab INR in Dialysis Patients on Warfarin
To determine whether point of care (POC) International Normalized Ratio (INR) test results correlate with plasma INR measures in hemodialysis patients.
- Trial name
- NCT00660946
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Atrium; Fibrillation, Chronic Kidney Diseases
Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
VISIONAIRE (Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE) trial will be a prospective randomized open-label with blinded endpoint adjudication trial including…
- Trial name
- VISIONAIRE (NCT06402851)
- Testing
- Anticoagulant Oral
- Where
- 6 sites in Brazil
- Volunteers
- 1,500 people
- Sponsor
- Hospital Sirio-Libanes
Atrial Fibrillation, Atrial Flutter
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)
People receiving dialysis are more likely to develop atrial fibrillation (AF), an irregular heartbeat that increases the risk of stroke.
- Conditions
- Atrial Fibrillation, Atrial Flutter, End Stage Kidney Disease (ESRD), Dialysis Patients
- Trial name
- SAFE-D2 (NCT07779746)
- Testing
- Eliquis, No oral anticoagulation
- Volunteers
- 848 people
- Sponsor
- Unity Health Toronto